Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01)

The role of zoledronic acid (ZA) when added to the neoadjuvant treatment of breast cancer (BC) in enhancing the clinical and pathological response of tumors is unclear. The effect of ZA on the antitumor effect of neoadjuvant chemotherapy has not prospectively been studied before. NEOZOTAC is a natio...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2014-05, Vol.25 (5), p.998-1004
Hauptverfasser:	Charehbili, A., van de Ven, S., Smit, V.T.H.B.M., Meershoek-Klein Kranenbarg, E., Hamdy, N.A.T., Putter, H., Heijns, J.B., van Warmerdam, L.J.C., Kessels, L., Dercksen, M., Pepels, M.J., Maartense, E., van Laarhoven, H.W.M., Vriens, B., Wasser, M.N., van Leeuwen-Stok, A.E., Liefers, G.J., van de Velde, C.J.H., Nortier, J.W.R., Kroep, J.R.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences bisphosphonates Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Breast Neoplasms - pathology Chemotherapy, Adjuvant Cyclophosphamide - administration & dosage Diphosphonates - administration & dosage Docetaxel Doxorubicin - administration & dosage Female Gynecology. Andrology. Obstetrics Humans Imidazoles - administration & dosage Mammary gland diseases Medical sciences menopausal status Middle Aged Multiple tumors. Solid tumors. Tumors in childhood (general aspects) neoadjuvant chemotherapy Neoadjuvant Therapy Neoplasm Staging Pharmacology. Drug treatments Prospective Studies Receptor, ErbB-2 - metabolism Taxoids - administration & dosage Treatment Outcome Tumors Zoledronic Acid
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!